Remdesivir had positive results on eGFR decline in adults with kidney damage, COVID-19
Click Here to Manage Email Alerts
Key takeaways:
- Remdesivir did not reduce adverse cardiovascular or kidney events in the study cohort.
- Remdesivir use was associated with a significant attenuation of eGFR decline during the study.
PHILADELPHIA — Remdesivir did not reduce adverse cardiovascular or kidney events in adults with underlying kidney damage hospitalized for COVID-19, a speaker here said.
However, the therapy was linked with a significant attenuation of eGFR decline.
“We wanted to look at a large cohort of patients who were hospitalized for COVID-19 [to examine] if remdesivir use could lower some of these long-term adverse outcomes,” Meghan E. Sise, MD, MS, of Massachusetts General Hospital in Boston, told Healio.
Patients who survive COVID-19 are at increased risk for cardiac and kidney sequelae, Sise added. Researchers sought to determine the long-term effects of remdesivir in this cohort.
Sise and colleagues conducted a propensity score-matched cohort study of 412 patients in that cohort, who survived more than 30 days, to compare the risk of major adverse cardiovascular events, major adverse kidney events and the slope of eGFR decline. Baseline eGFR at hospitalization was below 60 mL/min, and patients received remdesivir vs. historical comparators admitted prior to emergency use authorization for remdesivir.
Researchers found that by 18 months, there was no significant difference in the risk of major adverse cardiovascular or major adverse kidney events between the two groups. Remdesivir use was, however, associated with a significant attenuation of eGFR decline between 30 days and 18 months. The slope of eGFR decline was –0.77 mL/min/year in the remdesivir group vs. – 2.81 mL/min/year in the historical comparators, data showed.
“[We found] there was attenuation of the rapid eGFR decline that occurs in patients who get COVID-19,” Sise said. “We’re hopeful that suggests there may be some protective effect of giving patients with kidney disease antivirals so that they don’t get as sick. It will be a follow-up direction we want to go with this work.”
Collapse
Sise ME, et al. TH-PO1094. Presented at: ASN Kidney Week; Nov. 2-5, 2023; Philadelphia.
Read more about
Click Here to Manage Email Alerts